BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22734003)

  • 1. Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion.
    Onodera Y; Nam JM; Hashimoto A; Norman JC; Shirato H; Hashimoto S; Sabe H
    J Cell Biol; 2012 Jun; 197(7):983-96. PubMed ID: 22734003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
    Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
    Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
    Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
    PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery.
    Nam JM; Onodera Y; Mazaki Y; Miyoshi H; Hashimoto S; Sabe H
    EMBO J; 2007 Feb; 26(3):647-56. PubMed ID: 17255943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.
    Hashimoto S; Hirose M; Hashimoto A; Morishige M; Yamada A; Hosaka H; Akagi K; Ogawa E; Oneyama C; Agatsuma T; Okada M; Kobayashi H; Wada H; Nakano H; Ikegami T; Nakagawa A; Sabe H
    Proc Natl Acad Sci U S A; 2006 May; 103(18):7036-41. PubMed ID: 16636290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients.
    Sato H; Hatanaka KC; Hatanaka Y; Hatakeyama H; Hashimoto A; Matsuno Y; Fukuda S; Sabe H
    Cell Commun Signal; 2014 Mar; 12():17. PubMed ID: 24621372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
    Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
    Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
    Morishige M; Hashimoto S; Ogawa E; Toda Y; Kotani H; Hirose M; Wei S; Hashimoto A; Yamada A; Yano H; Mazaki Y; Kodama H; Nio Y; Manabe T; Wada H; Kobayashi H; Sabe H
    Nat Cell Biol; 2008 Jan; 10(1):85-92. PubMed ID: 18084281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.
    Haines E; Saucier C; Claing A
    J Biol Chem; 2014 Feb; 289(9):5687-703. PubMed ID: 24407288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
    Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
    Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin.
    Hwang MH; Cho KH; Jeong KJ; Park YY; Kim JM; Yu SL; Park CG; Mills GB; Lee HY
    Oncogene; 2017 Feb; 36(8):1102-1111. PubMed ID: 27524413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside.
    Sabe H; Hashimoto S; Morishige M; Hashimoto A; Ogawa E
    Cell Adh Migr; 2008; 2(2):71-3. PubMed ID: 19262097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARF6 and AMAP1 are major targets of
    Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
    Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation.
    Donnelly SK; Cabrera R; Mao SPH; Christin JR; Wu B; Guo W; Bravo-Cordero JJ; Condeelis JS; Segall JE; Hodgson L
    J Cell Biol; 2017 Dec; 216(12):4331-4349. PubMed ID: 29061650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells.
    Handa H; Hashimoto A; Hashimoto S; Sabe H
    Small GTPases; 2018 Sep; 9(5):420-426. PubMed ID: 27754741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells.
    Handa H; Hashimoto A; Hashimoto S; Sugino H; Oikawa T; Sabe H
    Cell Commun Signal; 2018 Dec; 16(1):94. PubMed ID: 30509302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL18-dependent translocation of AMAP1 is critical for epithelial to mesenchymal transition in breast cancer.
    Li H; Zhang D; Yu J; Liu H; Chen Z; Zhong H; Wan Y
    J Cell Physiol; 2018 Apr; 233(4):3207-3217. PubMed ID: 28834540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities.
    Onodera Y; Hashimoto S; Hashimoto A; Morishige M; Mazaki Y; Yamada A; Ogawa E; Adachi M; Sakurai T; Manabe T; Wada H; Matsuura N; Sabe H
    EMBO J; 2005 Mar; 24(5):963-73. PubMed ID: 15719014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.